KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biogen (BIIB) R&D In Process (2017 - 2021)

Biogen has reported R&D In Process over the past 5 years, most recently at $18.0 million for Q2 2021.

  • Quarterly results put R&D In Process at $18.0 million for Q2 2021, changed N/A from a year ago — trailing twelve months through Jun 2022 was $18.0 million (changed 0.0% YoY), and the annual figure for FY2021 was $18.0 million, down 76.0%.
  • R&D In Process for Q2 2021 was $18.0 million at Biogen, down from $75.0 million in the prior quarter.
  • Over the last five years, R&D In Process for BIIB hit a ceiling of $120.0 million in Q2 2017 and a floor of $10.0 million in Q1 2018.
  • Median R&D In Process over the past 4 years was $75.0 million (2018), compared with a mean of $57.2 million.
  • Peak annual rise in R&D In Process hit 37.5% in 2018, while the deepest fall reached 37.5% in 2018.
  • Biogen's R&D In Process stood at $120.0 million in 2017, then plummeted by 37.5% to $75.0 million in 2018, then changed by 0.0% to $75.0 million in 2020, then tumbled by 76.0% to $18.0 million in 2021.
  • The last three reported values for R&D In Process were $18.0 million (Q2 2021), $75.0 million (Q1 2020), and $75.0 million (Q4 2018) per Business Quant data.